Wedbush downgraded Inozyme (INZY) to Neutral from Outperform with a price target of $4, down from $7, after BioMarin entered into an agreement to acquire Inozyme for $4.00 per share in an all-cash transaction for a total consideration of $270M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma Merges with BioMarin for $270 Million
- BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio
- BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M
- Inozyme Pharma’s Strategic Focus and Promising Trial Data Earns Buy Rating
- Inozyme reports Q1 EPS (44c) vs (38c) last year